Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE)

Q: What does CUSIP 00773J202 represent in this 13F holders report?

CUSIP 00773J202 is the security identifier for SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share used to aggregate holder disclosures.

Q: How many institutions held SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share in Q1 2026?

195 institutional investors reported SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 00773J202

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, $0.0001 Par Value Per Share
Shares outstanding: 86,389,920
Total 13F shares: 83,100,719
Share change: +1,922,825
Total reported value: $4,185,493,446
Put/Call ratio: 8.8%
Price per share: $50.44
Number of holders: 195
Value change: +$119,766,143
Number of buys: 115
Number of sells: 59

Quarterly Holders Quick Answers

What is CUSIP 00773J202?
CUSIP 00773J202 identifies SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 00773J202:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	13%	11,638,819	$381,287,711	—	31 Dec 2025	13F
BlackRock, Inc.	13F 13D/G	Company	6.6% from 13D/G	5,522,101	$180,904,030	—	31 Dec 2025	13F 13D/G
RTW INVESTMENTS, LP	13F 13D/G	Company	6.2% from 13D/G	4,171,996	$136,674,589	—	31 Dec 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	4.7%	4,035,074	$132,189,024	—	31 Dec 2025	13F
Fairmount Funds Management LLC	13F 3/4/5	Company · Director	4.7%	4,018,101	$131,632,989	—	31 Dec 2025	13F 3/4/5
VR Adviser, LLC	13F	Company	4.3%	3,685,448	$120,735,276	—	31 Dec 2025	13F
Capital International Investors	13F	Company	4%	3,492,541	$114,415,643	—	31 Dec 2025	13F
PERCEPTIVE ADVISORS LLC	13F	Company	3.6%	3,069,225	$100,547,811	—	31 Dec 2025	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	3.3%	2,882,420	$94,428,079	—	31 Dec 2025	13F
Commodore Capital LP	13F	Company	2.8%	2,388,245	$78,238,906	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	2.6%	2,262,839	$74,130,606	—	31 Dec 2025	13F
TCG Crossover Management, LLC	13F	Company	2.2%	1,900,582	$62,263,066	—	31 Dec 2025	13F
TANG CAPITAL MANAGEMENT LLC	13D/G 13F	Company	2.4%	1,892,200	$62,064,160	-$42,895,840	31 Dec 2025	13D/G 13F
JANUS HENDERSON GROUP PLC	13F	Company	2.1%	1,829,009	$59,918,335	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.9%	1,659,140	$54,362,088	—	31 Dec 2025	13F
BRAIDWELL LP	13F	Company	1.9%	1,634,615	$53,549,987	—	31 Dec 2025	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	1.9%	1,621,620	$53,124,271	—	31 Dec 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	1.9%	1,601,882	$52,479,000	—	31 Dec 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	1.8%	1,549,284	$50,754,544	—	31 Dec 2025	13F
Paradigm Biocapital Advisors LP	13F	Company	1.7%	1,467,266	$48,067,634	—	31 Dec 2025	13F
Remedium Capital Partners, LLC	13F	Company	1.7%	1,456,231	$47,706,000	—	31 Dec 2025	13F
Affinity Asset Advisors, LLC	13F	Company	1.7%	1,432,591	$46,931,681	—	31 Dec 2025	13F
Venrock Healthcare Capital Partners III, L.P.	13D/G	—	4.6%	2,685,448	$40,335,429	$0	31 Dec 2024	13D/G
FRANKLIN RESOURCES INC	13F	Company	1.3%	1,109,274	$36,339,817	—	31 Dec 2025	13F
BAKER BROS. ADVISORS LP	13F 3/4/5	Company · Director	1.2%	1,000,000	$32,760,000	—	31 Dec 2025	13F 3/4/5
Pictet Asset Management Holding SA	13F	Company	1.1%	913,960	$29,941,330	—	31 Dec 2025	13F
Siren, L.L.C.	13F	Individual	0.95%	818,598	$26,817,270	—	31 Dec 2025	13F
Polar Capital Holdings Plc	13F	Company	0.86%	740,326	$24,253,080	—	31 Dec 2025	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	0.82%	710,626	$23,280,108	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.79%	680,566	$22,295,342	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	0.77%	662,351	$21,698,619	—	31 Dec 2025	13F
EMERALD ADVISERS, LLC	13F	Company	0.74%	636,109	$20,838,931	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.67%	574,622	$18,824,617	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.65%	561,023	$18,379,115	—	31 Dec 2025	13F
Blackstone Inc.	13F	Company	0.58%	500,998	$16,412,694	—	31 Dec 2025	13F
S.c.a. Candriam	13F	Individual	0.49%	425,534	$13,941,087	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.49%	419,727	$13,750,257	—	31 Dec 2025	13F
EMERALD MUTUAL FUND ADVISERS TRUST	13F	Company	0.48%	412,371	$13,509,274	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.32%	275,065	$9,011,129	—	31 Dec 2025	13F
Woodline Partners LP	13F	Company	0.31%	265,892	$8,710,622	—	31 Dec 2025	13F
Capital World Investors	13F	Company	0.23%	200,172	$6,557,635	—	31 Dec 2025	13F
ARMISTICE CAPITAL, LLC	13F	Company	0.23%	196,426	$6,434,916	—	31 Dec 2025	13F
Bank of New York Mellon Corp	13F	Company	0.22%	192,830	$6,317,104	—	31 Dec 2025	13F
HighVista Strategies LLC	13F	Company	0.22%	188,206	$6,165,629	—	31 Dec 2025	13F
SILVERARC CAPITAL MANAGEMENT, LLC	13F	Company	0.22%	187,737	$6,150,264	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.21%	182,734	$5,986,378	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.21%	182,524	$5,979,487	—	31 Dec 2025	13F
Universal- Beteiligungs- und Servicegesellschaft mbH	13F	Individual	0.2%	171,211	$5,608,873	—	31 Dec 2025	13F
Nuveen, LLC	13F	Company	0.17%	150,980	$4,946,105	—	31 Dec 2025	13F
Invesco Ltd.	13F	Company	0.17%	150,934	$4,944,597	—	31 Dec 2025	13F

Institutional Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE) as of Q1 2026

As of 31 Mar 2026, Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE) was held by 195 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 83,100,719 shares. The largest 10 holders included FMR LLC, BlackRock, Inc., RTW INVESTMENTS, LP, Fairmount Funds Management LLC, PERCEPTIVE ADVISORS LLC, Venrock Adviser, LLC, VANGUARD CAPITAL MANAGEMENT LLC, Driehaus Capital Management LLC, STATE STREET CORP, and Paradigm Biocapital Advisors LP. This page lists 195 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

152

Q1 2026 holders

195

Holder diff

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.